Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GS010 in LHON (RESCUE)
NCT02652767Phase 3Completed
- Sponsor
- GenSight Biologics
- Start
- Feb 2016
- Primary completion
- Aug 2018
- Countries
- 5
01
Overview
Phase 3, randomised, double-blind trial of lenadogene nolparvovec in Leber hereditary optic neuropathy (LHON), sponsored by GenSight Biologics. Primary endpoint: ETDRS Visual Acuity at 48 weeks. Started Feb 2016; status: completed.
02
Drugs
lenadogene nolparvovec
03
Conditions
Leber hereditary optic neuropathy (LHON)
Beyond the preview
Go deeper on NCT02652767.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02652767.